AbCellera Biologics (NASDAQ:ABCL) Announces Earnings Results

AbCellera Biologics (NASDAQ:ABCL - Get Free Report) posted its earnings results on Thursday. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.15) by $0.04, Zacks reports. The firm had revenue of $5.10 million for the quarter, compared to analyst estimates of $7.58 million. AbCellera Biologics had a negative return on equity of 15.73% and a negative net margin of 533.32%.

AbCellera Biologics Price Performance

ABCL traded down $0.23 on Monday, reaching $2.36. The company's stock had a trading volume of 3,726,068 shares, compared to its average volume of 2,215,927. The business's 50 day moving average is $3.10 and its 200 day moving average is $2.84. AbCellera Biologics has a 1 year low of $2.31 and a 1 year high of $5.13. The stock has a market cap of $697.06 million, a price-to-earnings ratio of -3.87 and a beta of 0.42.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. KeyCorp decreased their price target on shares of AbCellera Biologics from $5.00 to $4.00 and set an "overweight" rating on the stock in a research note on Wednesday, January 8th. Benchmark restated a "hold" rating on shares of AbCellera Biologics in a report on Monday. Finally, Stifel Nicolaus dropped their price objective on shares of AbCellera Biologics from $12.00 to $10.00 and set a "buy" rating for the company in a research report on Friday.

About AbCellera Biologics

AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.